Milou‐Daniel Drici

2.7k total citations
73 papers, 1.6k citations indexed

About

Milou‐Daniel Drici is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Pharmacology. According to data from OpenAlex, Milou‐Daniel Drici has authored 73 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Cardiology and Cardiovascular Medicine, 15 papers in Molecular Biology and 14 papers in Pharmacology. Recurrent topics in Milou‐Daniel Drici's work include Cardiac electrophysiology and arrhythmias (14 papers), Pharmacovigilance and Adverse Drug Reactions (14 papers) and Drug-Induced Adverse Reactions (9 papers). Milou‐Daniel Drici is often cited by papers focused on Cardiac electrophysiology and arrhythmias (14 papers), Pharmacovigilance and Adverse Drug Reactions (14 papers) and Drug-Induced Adverse Reactions (9 papers). Milou‐Daniel Drici collaborates with scholars based in France, United States and Italy. Milou‐Daniel Drici's co-authors include Björn C. Knollmann, Raymond L. Woosley, Sylvie Diochot, Michel Lazdunski, Fanny Rocher, Alexandre O. Gérard, Jacques Barhanin, Danielle Moinier, Michel Fink and Nadège Parassol and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and Circulation.

In The Last Decade

Milou‐Daniel Drici

67 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Milou‐Daniel Drici France 21 666 534 264 137 136 73 1.6k
Stefano D’Errico Italy 24 228 0.3× 270 0.5× 258 1.0× 126 0.9× 110 0.8× 121 1.7k
Brian R. Overholser United States 18 484 0.7× 196 0.4× 160 0.6× 38 0.3× 141 1.0× 64 1.2k
Walter K. Kraft United States 29 255 0.4× 213 0.4× 283 1.1× 27 0.2× 161 1.2× 128 2.5k
Cristian Palmière Switzerland 27 175 0.3× 302 0.6× 49 0.2× 293 2.1× 124 0.9× 136 2.3k
Guillermo Di Girolamo Argentina 22 241 0.4× 237 0.4× 74 0.3× 27 0.2× 116 0.9× 107 1.3k
Carla Carnovale Italy 23 116 0.2× 177 0.3× 129 0.5× 192 1.4× 168 1.2× 101 1.4k
Tiansheng Wang United States 27 116 0.2× 389 0.7× 210 0.8× 77 0.6× 272 2.0× 96 2.0k
Alessandro Ceschi Switzerland 22 67 0.1× 203 0.4× 187 0.7× 164 1.2× 205 1.5× 94 1.5k
Frank Andersohn Germany 24 358 0.5× 163 0.3× 117 0.4× 75 0.5× 381 2.8× 59 2.6k
Huafen Liu China 16 121 0.2× 260 0.5× 631 2.4× 234 1.7× 230 1.7× 36 1.6k

Countries citing papers authored by Milou‐Daniel Drici

Since Specialization
Citations

This map shows the geographic impact of Milou‐Daniel Drici's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Milou‐Daniel Drici with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Milou‐Daniel Drici more than expected).

Fields of papers citing papers by Milou‐Daniel Drici

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Milou‐Daniel Drici. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Milou‐Daniel Drici. The network helps show where Milou‐Daniel Drici may publish in the future.

Co-authorship network of co-authors of Milou‐Daniel Drici

This figure shows the co-authorship network connecting the top 25 collaborators of Milou‐Daniel Drici. A scholar is included among the top collaborators of Milou‐Daniel Drici based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Milou‐Daniel Drici. Milou‐Daniel Drici is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gérard, Alexandre O., et al.. (2025). Safety profile of belatacept in a real-life setting: disproportionality analysis of the WHO pharmacovigilance database. BMC Pharmacology and Toxicology. 26(1). 147–147.
2.
Gérard, Alexandre O., et al.. (2025). Evaluating and leveraging large language models in clinical pharmacology and therapeutics assessment: From exam takers to exam shapers. British Journal of Clinical Pharmacology. 1 indexed citations
3.
Destère, Alexandre, et al.. (2024). An artificial intelligence algorithm for co‐clustering to help in pharmacovigilance before and during the COVID‐19 pandemic. British Journal of Clinical Pharmacology. 90(5). 1258–1267. 2 indexed citations
4.
Cohen, Mikaël, et al.. (2024). Dental Adverse Effects of Anti-CD20 Therapies. Neurology and Therapy. 13(3). 917–930. 2 indexed citations
5.
6.
Gérard, Alexandre O., Alexandre Destère, Florence Askénazy, et al.. (2024). Cardiac and metabolic safety profile of antipsychotics in youths: A WHO safety database analysis. Psychiatry Research. 334. 115786–115786. 4 indexed citations
7.
Grandvuillemin, Aurélie, et al.. (2023). Pharmacovigilance follow-up of patients in the context of the COVID-19 pandemic. Therapies. 78(5). 523–529. 5 indexed citations
8.
Gérard, Alexandre O., Alexandre Destère, Michaël Loschi, et al.. (2023). CAR-T Cells and the Kidney: Insights from the WHO Safety Database. BioDrugs. 37(4). 521–530. 7 indexed citations
9.
Gérard, Alexandre O., Alexandre Destère, Florence Askénazy, et al.. (2023). Iatrogenic triggers for anorexia nervosa and bulimia nervosa: A WHO safety database disproportionality analysis. Psychiatry Research. 327. 115415–115415. 2 indexed citations
10.
Gérard, Alexandre O., et al.. (2023). The Neuropsychiatric Safety Profile of Lasmiditan: A Comparative Disproportionality Analysis with Triptans. Neurotherapeutics. 20(5). 1305–1315. 3 indexed citations
11.
Gérard, Alexandre O., et al.. (2023). Drug-related catatonia in youths: real-world insights from the WHO Safety Database. European Child & Adolescent Psychiatry. 33(5). 1383–1393. 5 indexed citations
12.
Destère, Alexandre, et al.. (2023). A HPLC-DAD method to facilitate large-scale therapeutic drug monitoring of dalbavancin. Journal of Chromatography B. 1222. 123694–123694. 5 indexed citations
13.
Fernandez, Arnaud, Alexandre O. Gérard, Fanny Rocher, et al.. (2022). Adverse Drug Reactions of Olanzapine, Clozapine and Loxapine in Children and Youth: A Systematic Pharmacogenetic Review. Pharmaceuticals. 15(6). 749–749. 3 indexed citations
14.
Gérard, Alexandre O., Bruno Giordana, Fanny Rocher, et al.. (2022). Medications as a Trigger of Sleep-Related Eating Disorder: A Disproportionality Analysis. Journal of Clinical Medicine. 11(13). 3890–3890. 9 indexed citations
15.
Gérard, Alexandre O., A Sicard, Atul Pathak, et al.. (2022). New Strategies for Volume Control in Patients with Diabetes Mellitus, a Narrative Review. Pharmaceutics. 14(8). 1569–1569. 2 indexed citations
16.
Gérard, Alexandre O., et al.. (2022). Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database. The Journal of Headache and Pain. 23(1). 53–53. 30 indexed citations
17.
Gérard, Alexandre O., Marine Andreani, Nadège Parassol, et al.. (2021). Immune checkpoint inhibitors-induced nephropathy: a French national survey. Cancer Immunology Immunotherapy. 70(11). 3357–3364. 11 indexed citations
18.
Lafeuillade, Alain, et al.. (2019). Are current guidelines adapted for patient eligibility to PrEP? A case report. BMC Infectious Diseases. 19(1). 601–601.
19.
Bardy, Guillaume, et al.. (2015). Is anti-factor Xa chromogenic assay for Rivaroxaban appropriate in clinical practice? Advantages and comparative drawbacks. Thrombosis Research. 136(2). 396–401. 16 indexed citations
20.
Tuppin, Philippe, Christine de Peretti, A. Fagot‐Campagna, et al.. (2013). First hospitalization for heart failure in France in 2009: Patient characteristics and 30-day follow-up. Archives of cardiovascular diseases. 106(11). 570–585. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stefano D’Errico Breakdown of academic impact, for papers by Brian R. Overholser Breakdown of academic impact, for papers by Walter K. Kraft Breakdown of academic impact, for papers by Cristian Palmière Breakdown of academic impact, for papers by Guillermo Di Girolamo Breakdown of academic impact, for papers by Carla Carnovale Breakdown of academic impact, for papers by Tiansheng Wang Breakdown of academic impact, for papers by Alessandro Ceschi Breakdown of academic impact, for papers by Frank Andersohn Breakdown of academic impact, for papers by Huafen Liu
Rankless by CCL
2026